Although consensus concerning the best cut-off value has yet to be achieved, the integration of tumor biology (including AFP) into the selection criteria was recommended with strong strength for both the deceased and LDLT in the working group report from the 2020 International Liver Transplantation Society transplant oncology consensus conference [39]. The gene discussed is AFP; the disease is neoplasm.